(0.07%) 5 473.24 points
(0.11%) 39 155 points
(0.38%) 17 786 points
(0.06%) $80.88
(-3.66%) $2.66
(-0.79%) $2 312.30
(0.16%) $28.92
(3.67%) $1 022.60
(0.28%) $0.936
(0.67%) $10.68
(0.44%) $0.792
(-0.27%) $87.25
Live Chart Being Loaded With Signals
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases...
Stats | |
---|---|
今日成交量 | 49 513 |
平均成交量 | 65 914 |
市值 | 551.09M |
EPS | $-0.630 ( Q1 | 2024-05-14 ) |
下一个收益日期 | ( $-0.720 ) 2024-08-13 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-5.25 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.106 (0.62%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-06-20 | Ra Capital Management, L.p. | Buy | 13 000 | Stock Option (Right to Buy) |
2024-06-20 | Henson Heidi | Buy | 13 000 | Stock Option (Right to Buy) |
2024-06-20 | Keating Laurie | Buy | 13 000 | Stock Option (Right to Buy) |
2024-06-20 | Resnick Joshua | Buy | 13 000 | Stock Option (Right to Buy) |
2024-06-20 | Ashton Christopher | Buy | 13 000 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
95.80 |
Last 97 transactions |
Buy: 15 695 917 | Sell: 4 057 104 |
音量 相关性
PepGen Inc. 相关性 - 货币/商品
PepGen Inc. 财务报表
Annual | 2023 |
营收: | $0 |
毛利润: | $-1.18M (0.00 %) |
EPS: | $-3.30 |
FY | 2023 |
营收: | $0 |
毛利润: | $-1.18M (0.00 %) |
EPS: | $-3.30 |
FY | 2022 |
营收: | $0 |
毛利润: | $-493 000 (0.00 %) |
EPS: | $-2.91 |
FY | 2021 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-3.53 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
PepGen Inc.
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。